Indivior Pharmaceuticals, Inc.

This annual report contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: our financial guidance including revenue, operating and profit/gross margins for 2026, including revenue by product or geography, and our medium- and long-term growth outlook; our expectations regarding long‑term market growth, including the LAI category, and our ability to increase LAI penetration; strategic priorities, strategies for value creation, and operational goals; our product development pipeline and potential future products, expectations regarding clinical trials and the timing of such trials, regulatory approval of such product candidates, the timing of such approvals, and the timing of commercial launch of such products or product candidates, and eventual annual revenues of such future products; expectations regarding the adequacy of our raw materials and supply chain; expected levels of operating expenses including R&D expense, operational savings, and expected benefits from our reinvestment efforts; expectations regarding costs and future production at our Raleigh Manufacturing Facility; other expected capital expenses and investments; expectations regarding current estimates, including those related to exiting certain businesses; expected future levels of interest expense and income; our expectation that we will realize our deferred tax assets; our expectation that the ultimate resolution of our current legal matters will not have a material adverse effect on our financial position or liquidity; our expectation that we will meet our obligations as they come due over the next 12 months from cash on hand and operations, and other statements containing the words "believe," "anticipate," "plan," "expect," "intend," "estimate," "forecast," “strategy,” “target,” “guidance,” “outlook,” “potential,” "project," "priority," "may," "will," "should," "would," "could," "can," "outlook," "guidance," the negatives thereof, and variations thereon and similar expressions. By their nature, such forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in these forward-looking statements.

The forward-looking statements in this annual report are made based upon our current expectations and beliefs concerning future events and involve a number of known and unknown risks and uncertainties. Such forward-looking statements are based on numerous assumptions regarding our present and future business strategy and the environment in which we operate, which may prove to be inaccurate. In particular, our actual results, performance or achievements or industry results could be affected by, among other things:

•We are subject to risks related to the manufacture and distribution of our products and must adhere to stringent manufacturing processes.

•We rely heavily on SUBLOCADE for a significant portion of our revenues;

•Our revenues may grow at a slower than expected rate or decline due to many factors;

•Our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline;

•The uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process;

•The litigation to which we are or may become a party;

•Our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs;

•Risks related to the manufacture and distribution of our products, most of which contain controlled substances;

•Our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions;

•Unintended side effects caused by the clinical study or commercial use of our products;

•Our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry;

•Congress may reduce Medicaid funding;

•Competition;

•Actual costs to exit various businesses may differ materially from our estimates

•Our use of hazardous materials in our manufacturing facilities;

•Our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights;

•The risks related to product liability claims or product recalls;

•The significant number of laws and regulations that we are subject to, including due to the international nature of our business;

•Macroeconomic trends and other global developments such as pandemics and government responses thereto;

•The terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due;

•Changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets;

•Volatility in our share price due to factors unrelated to our operating performance; and

•Such other factors as set out in “Item 1A. Risk Factors” and“Item 7. Management's Discussion & Analysis—Operating Results.”

Forward-looking statements contained in this annual report apply only at the date of this annual report. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.